# TABLE OF CONTENTS

- Workshop Sponsors ................................................................. 2
- Program Schedule ............................................................... 3
- Co-Chairs ................................................................. 4
- Speakers ................................................................. 4
- Speaker Bios ............................................................... 5
- Disclosure of Relevant Financial Relationships ....................... 7
ONCOLYTIC VIRUSES WORKSHOP SPONSORS
The American Society of Gene & Cell Therapy is honored to acknowledge the following organization for its support of the Oncolytic Viruses Workshop:

AstraZeneca
# Oncolytic Viruses Workshop

## PROGRAM

All times are listed in Eastern Daylight Time (EDT UTC -4).

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM - 4:35 PM</td>
<td>CO-CHAIRS: Yuman Fong, MD and Kah Whye Peng, PhD</td>
</tr>
<tr>
<td></td>
<td>ROOM: Ballroom A</td>
</tr>
<tr>
<td>1:00 PM – 1:05 PM</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Kah Whye Peng, PhD</td>
</tr>
<tr>
<td>1:05 PM – 1:35 PM</td>
<td>Choosing the OV Platform: Considerations</td>
</tr>
<tr>
<td></td>
<td>Stephen J. Russell, MD, PhD</td>
</tr>
<tr>
<td>1:35 PM – 2:05 PM</td>
<td>Engineering strategies of oncolytic viruses – Engaging both innate and adaptive immunity</td>
</tr>
<tr>
<td></td>
<td>Liang Deng, MD, PhD</td>
</tr>
<tr>
<td>2:05 PM PM - 2:30 PM</td>
<td>HSV as OV</td>
</tr>
<tr>
<td></td>
<td>Robert S. Coffin, PhD</td>
</tr>
<tr>
<td>2:30 PM - 2:55 PM</td>
<td>Advances in OV Development 4 Years after T-VEC Approval: Where Are We Heading?</td>
</tr>
<tr>
<td></td>
<td>Robert H. I. Andtbacka, MD, CM</td>
</tr>
<tr>
<td>2:55 PM - 3:05 PM</td>
<td>Break</td>
</tr>
<tr>
<td>3:05 PM - 3:35 PM</td>
<td>Outstanding Big Questions in OV R&amp;D and Design</td>
</tr>
<tr>
<td></td>
<td>Leonard Seymour</td>
</tr>
<tr>
<td>3:35 - 4:05 PM</td>
<td>Industrial Trials in Oncolytic Therapy</td>
</tr>
<tr>
<td></td>
<td>Yuman Fong, MD</td>
</tr>
<tr>
<td>4:05 PM - 4:35 PM</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

*Eastern Time Zone (EDT UTC -4)*
CO-CHAIRS

Yuman Fong, MD
City of Hope Medical Center
Duarte, CA

Kah Whye Peng, PhD
Mayo Clinic
Rochester, MN

SPEAKERS

Robert H Andtbacka, MD, CM
Seven and Eight Biopharmaceuticals Inc.
Edison, NJ

Robert S. Coffin, PhD
Replimune
Woburn, MA

Liang Deng, MD, PhD
Memorial Sloan Kettering Center
New York, NY

Yuman Fong, MD
City of Hope Medical Center
Duarte, CA

Kah Whye Peng, PhD
Mayo Clinic
Rochester, MN

Stephen J. Russell, MD, PhD
Mayo Clinic
Rochester, MN

Leonard W Seymour
University of Oxford
Oxford, United Kingdom
Robert Andtbacka, MD, CM
Robert Andtbacka, MD, CM, FACS, FRCSC is an internationally renowned, board certified surgeon, tenured professor of surgical oncology and researcher. Before joining the Huntsman Cancer Institute (HCI) at the University of Utah in 2006, he completed a 3-year fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center. He received his medical degree and training in general surgery at McGill University. At HCI, Dr. Andtbacka specialized in surgery for melanoma, skin cancer, and soft tissue sarcomas. He established an internationally recognized comprehensive surgical and clinical research program, resulting in National Institute of Health (NIH) funding for developing novel imaging methods to detect lymphatic spread of cancer cells and to determine tumor margins. Dr. Andtbacka was instrumental in the melanoma practice changing Multicenter Selective Lymphadenectomy Trial II (MSLT-II). He has been the principal investigator in over 30 investigator-initiated, institutional, and multi-institutional clinical trials. He is a world leader in novel intratumoral oncolytic immunotherapies and was the lead investigator on the OPTIM Phase III clinical trial, which lead to the FDA approval of talimogene laherparepvec (T-VEC) in patient with unresectable metastatic melanoma. Dr. Andtbacka has presented his research at over 100 national and international meetings and has authored over 70 peer-reviewed publications, 4 book chapters, and over 50 webinars and podcasts. Dr. Andtbacka served on the Melanoma Committee for the National Comprehensive Cancer Network (NCCN), and as the Utah State Chair for the Commission on Cancer. He was the Chief Medical Officer and Director of Clinical Research at Vestan Medical Imaging, where he led the clinical development of fluorescent sentinel lymph node imaging in patients with melanoma and breast cancer. Dr. Andtbacka is currently the Chief Medical Officer at Seven and Eight Biopharmaceuticals, a biotechnology company focusing on developing immuno-oncology therapies.

Robert S. Coffin, PhD
Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

Liang Deng, MD, PhD
Dr. Liang Deng received her BS degree from the University of Rochester, and her PhD and MD degrees from Memorial Sloan Kettering Cancer Center (MSKCC) and Weill Cornell Medical College. She is currently an Associate Member and Associate Attending Physician at MSKCC. She is a board-certified dermatologist specializing in melanoma and viral-associated skin malignancies. Her laboratory research has been focused on studying virus-host interaction and the development of vaccinia-based cancer immunotherapeutics. Her previous work demonstrated that intratumoral injection of inactivated modified vaccinia virus Ankara (MVA) turns “cold” tumors into “hot” tumors, which results in enhanced responsiveness to immune checkpoint blockade (ICB) therapy. Based on these findings, her research program focuses on developing recombinant MVA or vaccinia to elicit strong “in situ vaccination” effects used either alone or in combination with ICB. Her research has been supported by the NIH, the Dermatology Foundation, American Skin Association, Parker Institute for Cancer Immunotherapy, Technology Development Award at MSKCC, and IMVAQ Therapeutics, a biotech company she and her colleagues at MSKCC co-founded.

Yuman Fong, MD
Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is currently the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center. Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery. He also helped usher in robotic techniques for HPB surgery. He is editor of the SAGES Atlas of Robotic Surgery. For his clinical work, he was awarded the Layton F. Rikkers Master Clinician Award from the SSAT. He has assisted in the design and deployment of many novel surgical tools and gene manipulation tools. His work in medical engineering has led to his election to the American Institute of Medical and Biologic Engineering. Dr. Fong’s early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped establish the field of innate immunity. His laboratory focus over the last 20 years has been in the field of gene therapy. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.
Stephen J. Russell, MD, PhD

The research interests of Stephen J. Russell, MD, PhD, center on demonstrating the value of oncolytic virotherapy as a new modality for the treatment of cancer. Viruses from several families are engineered in Dr. Russell’s laboratory. His team currently has oncolytic projects focusing on measles, vesicular stomatitis virus (VSV), coxsackievirus A21 (CVA21) and Mengo virus. Nonreplicative adeno-associated viruses, lentivirus and adenovirus vectors also are used extensively. Virus tropisms are engineered by the display of single-chain antibodies and other targeting proteins on viral surface glycoproteins such as measles or lentiviruses, or by incorporating microRNA target sequences at strategic sites in the viral genome, using CVA21, VSV or Mengo virus. These targeting approaches were developed in Dr. Russell’s laboratory. In vivo, virus propagation is noninvasively monitored by engineering the oncolytic virus genomes to encode secretable marker peptides, like carcinoembryonic antigen, or the thyroidal sodium iodide symporter, which concentrates radioactive iodine into virus-infected tissues. These oncolytic monitoring approaches were also developed in Dr. Russell’s laboratory, and the technology has been advanced to clinical testing in phase I clinical trials at Mayo Clinic.

Leonard Seymour

Len Seymour is Professor of Gene Therapy at the University of Oxford, where he specialises in the use of genetic engineering and virology in treatment of cancer. He leads a university research containing some twenty scientists with expertise across the spectrum of virology and cell and synthetic biology. In 2003 he was the Founding Chairman of the British Society for Gene and Cell Therapy, aiming to establish this new technology as a mainstream medical discipline. He has strong interests in both clinical and commercial translation of sciences and is a founding scientist of Psioxus Therapeutics, the Native Antigen Company and Oxford Genetics.
## DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

<table>
<thead>
<tr>
<th>Name</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert H Andtbacka, MD, CM</td>
<td>Seven and Eight Biopharmaceuticals Inc., Salary, Employment; Novartis, Salary, Employment; Merck, Salary, Employment</td>
</tr>
<tr>
<td>Robert S. Coffin, PhD</td>
<td>Replimune, Salary, Stock, Founder and President</td>
</tr>
<tr>
<td>Liang Deng, MD, PhD</td>
<td>IMVAQ Therapeutics, Co-Founder</td>
</tr>
</tbody>
</table>
ASGCT
Portland
24TH ANNUAL MEETING
May 12th–15th, 2021